ALTITUDE-AD (NCT06335173) is a Phase 2 double-blind, randomized, placebo-controlled clinical trial evaluating the efficacy and safety of intravenous Sabirnetug (also known as ALZ-201) in patients with early Alzheimer's disease. Sponsored by Acumen Pharmaceuticals, this trial represents a critical step in developing novel disease-modifying therapies targeting amyloid-beta pathophysiology.
Sabirnetug is a monoclonal antibody designed to selectively target and neutralize toxic amyloid-beta oligomers, which are widely recognized as the primary drivers of synaptic dysfunction and neurodegeneration in AD. Unlike earlier antibody approaches that focused primarily on monomeric Aβ or plaque removal, Sabirnetug specifically targets the soluble, synaptotoxic oligomeric species believed to be most pathogenic.
This Phase 2 trial builds upon earlier preclinical work demonstrating that ALZ-201 effectively reduces Aβ oligomer-induced synaptic damage in cellular and animal models. The selection of the integrated Alzheimer's Disease Rating Scale (iADRS) as the primary endpoint reflects the growing recognition that composite cognitive-functional measures capture clinically meaningful treatment effects more sensitively than individual cognitive scales alone.
| Parameter |
Value |
| NCT Number |
NCT06335173 |
| Phase |
PHASE2 |
| Status |
ACTIVE_NOT_RECRUITING |
| Sponsor |
Acumen Pharmaceuticals |
| Enrollment |
542 participants |
| Enrollment Type |
ACTUAL |
| Study Type |
INTERVENTIONAL |
| Start Date |
2024-02-29 00:00:00 |
| Completion Date |
2026-10-01 00:00:00 |
| Last Updated |
2025-10-27 00:00:00 |
- Alzheimer Disease (Early Stage, including MCI due to AD and mild AD dementia)
Sabirnetug (ALZ-201) represents a next-generation therapeutic approach that specifically targets the soluble amyloid-beta oligomeric species that are now recognized as the most synaptotoxic form of Aβ in AD pathogenesis.
Pathological Rationale:
- Amyloid-beta monomers are naturally occurring peptides that, in healthy brains, are cleared efficiently
- Aβ oligomers form when Aβ peptides aggregate into soluble, diffusible species containing 2-50 monomers
- Plaques (insoluble Aβ deposits) may actually serve as a "sink" for toxic oligomers, and their removal without targeting oligomers directly may provide limited clinical benefit
The oligomer hypothesis proposes that soluble Aβ oligomers, rather than plaques themselves, are the primary drivers of:
- Synaptic dysfunction and loss
- Dendritic spine degeneration
- Impaired long-term potentiation (LTP)
- Neuroinflammation through microglial activation
- Progressive cognitive decline
¶ Antibody Design and Specificity
Sabirnetug is designed to:
- Selectively bind Aβ oligomers with high affinity, while showing minimal binding to monomers and plaques
- Neutralize synaptotoxic activity by blocking oligomer interactions with neuronal receptors
- Promote clearance of oligomeric species through Fc-mediated microglial phagocytosis
- Avoid excessive plaque disruption that might trigger inflammatory responses
This selective targeting approach differs from earlier-generation anti-Aβ antibodies like aducanumab and lecanemab, which primarily target plaque amyloid with varying degrees of efficacy.
The amyloid cascade hypothesis, first proposed in 1992 and subsequently refined, posits that Aβ accumulation is the initiating event in AD pathogenesis:
flowchart TD
A["Aβ Monomer Production"] --> B["Aβ Oligomerization"]
B --> C["Soluble Aβ Oligomers"]
C --> D["Synaptic Dysfunction"]
D --> E["Tau Hyperphosphorylation"]
E --> F["Neurofibrillary Tangle Formation"]
C --> G["Microglial Activation"]
G --> H["Neuroinflammation"]
D --> I["Neuronal Loss"]
I --> J["Cognitive Decline"]
However, the failure of multiple Aβ-targeting therapies has led to significant reappraisal of this model, with current understanding emphasizing:
- Aβ as necessary but not sufficient for disease
- Multiple upstream triggers (genetic, environmental, aging-related)
- Complex interactions between Aβ, tau, and neuroinflammation
This is a Phase 2, randomized, double-blind, placebo-controlled clinical trial with the following key features:
| Design Element |
Description |
| Randomization |
1:1:1 to two active dose cohorts or placebo |
| Duration |
78 weeks (approximately 18 months) |
| Blinding |
Double-blind (participant and investigator) |
| Setting |
Multi-center, international |
| Phase |
Phase 2 |
The trial evaluates multiple dose levels to establish:
- Dose-response relationship for efficacy
- Safety and tolerability across dose range
- Pharmacodynamic markers of target engagement
- Optimal dosing regimen for Phase 3
Integrated Alzheimer's Disease Rating Scale (iADRS):
- Composite measure combining:
- ADAS-Cog14 (cognitive subscale, 14 items) - assesses memory, language, praxis
- ADCS-iADL (functional subscale) - assesses daily living activities
- Range: 0-146 (lower = worse function)
- Designed to capture both cognitive and functional domains in a single sensitive measure
- Previously validated in trials of early AD populations
Secondary endpoints likely include:
- Amyloid PET (Centiloid reduction) - measure of Aβ plaque burden
- CSF biomarkers - Aβ42/40 ratio, tau, p-tau levels
- Clinical measures - MMSE, CDR-SB
- Safety - adverse events, SAEs, immunogenicity
Disease-related:
- Age 50-85 years
- Clinical diagnosis of MCI due to AD or mild AD dementia
- MMSE score 20-30 (or equivalent)
- Confirmed amyloid positivity (PET or CSF)
Other:
- Stable background medications for >4 weeks
- Adequate caregiver/support person availability
- Ability to comply with protocol requirements
- Neurological: Stroke, significant vascular disease, other dementia types
- Psychiatric: Severe depression, psychosis, active suicidal ideation
- Medical: Uncontrolled hypertension, diabetes, cardiac disease
- Medications: Current anti-Aβ therapy, immunomodulatory agents
Alzheimer's disease (AD) is the most common cause of dementia, accounting for approximately 60-80% of all dementia cases. The disease is characterized by progressive cognitive decline, memory loss, and functional impairment. Pathologically, AD is associated with the accumulation of amyloid-beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain.
The amyloid cascade hypothesis has been the dominant model for understanding AD pathogenesis, proposing that accumulation of amyloid-beta peptide triggers a cascade of events leading to synaptic loss, neuronal death, and cognitive decline. However, recent clinical trials have revealed the complexity of AD pathophysiology and the need for multi-target therapeutic approaches.
A key component of AD pathophysiology that Sabirnetug may address through indirect effects on oligomer-mediated microglial activation:
The innate immune system plays a critical role in AD pathogenesis, with microglia and astrocytes contributing to both protective and pathogenic processes:
- Pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) are elevated in AD brain and correlate with disease severity
- Microglial morphometry shows disease-associated changes in density and distribution around plaques
- Complement system activation contributes to synaptic elimination
- Aβ oligomers directly activate microglia through pattern recognition receptors
Understanding Sabirnetug's effects on neuroinflammation will be important for evaluating its overall disease-modifying potential.
This trial represents one of several ongoing efforts to develop effective Aβ-targeted therapies:
| Agent |
Company |
Target |
Stage |
Key Differentiator |
| Lecanemab |
Eisai/Biogen |
Aβ protofibrils |
Approved |
Early approval, confirmatory trial |
| Donanemab |
Eli Lilly |
N-terminal Aβ |
Approved |
Tartrate, staged dosing |
| Remternetug |
Eli Lilly |
Aβ oligomers |
Phase 3 |
Subcutaneous administration |
| Sabirnetug |
Acumen |
Aβ oligomers |
Phase 2 |
Selective oligomer targeting |
The field has learned important lessons from previous Aβ antibody trials:
- Patient selection - Treating earlier disease stages appears more effective
- Endpoint sensitivity - Composite measures like iADRS may be more sensitive
- Biomarker correlation - Amyloid reduction necessary but not sufficient
- Safety monitoring - ARIA requires careful imaging surveillance
- Combination approaches - Rationale for multi-target therapy
If successful, Sabirnetug would:
- Validate oligomer targeting as an effective therapeutic strategy
- Provide treatment option with novel mechanism of action
- Inform precision medicine approaches based on biomarker profiles
- Enable combination therapy development with other mechanisms
The trial is being conducted at multiple centers worldwide, including sites in:
- California, United States (multiple locations including Carlsbad, Fullerton, Irvine, Long Beach, Santa Ana)
- Additional international locations (specific sites to be confirmed)
¶ Safety and Tolerability Considerations
All anti-Aβ antibodies carry the risk of amyloid-related imaging abnormalities (ARIA), a class of imaging findings that include:
ARIA-E (Edema):
- Characterized by hyperintense signal on FLAIR MRI
- Represents vasogenic edema or sulcal effusions
- Typically reversible upon drug discontinuation
- Risk factors include ApoE ε4 carrier status, higher dosing
ARIA-H (Hemorrhage):
- Includes cerebral microhemorrhages, hemosiderosis
- May occur with or without ARIA-E
- Generally asymptomatic but requires monitoring
Monitoring Protocol:
- Baseline MRI before first dose
- MRI at Week 12, Week 24, and as clinically indicated
- Careful monitoring for symptoms (headache, confusion, visual changes)
- Dose adjustment guidelines based on ARIA severity
As a monoclonal antibody, Sabirnetug may elicit anti-drug antibodies (ADAs):
- ADAs could affect PK/PD and reduce efficacy
- Potential for infusion reactions
- Long-term immunogenicity monitoring in extension studies
| Parameter |
Lecanemab |
Donanemab |
Sabirnetug |
| Target |
Protofibrils |
N-terminal |
Oligomers |
| Dosing |
Q2W IV |
Q4W IV |
TBD |
| ARIA-E rate |
~10% |
~24% |
TBD |
| ARIA-H rate |
~17% |
~31% |
TBD |
| Infusion time |
60 min |
60 min |
TBD |
¶ Competitive Landscape and Market Context
The Alzheimer's disease treatment market represents one of the largest unmet medical needs:
- Global AD population: ~55 million (2023)
- Projected to reach 139 million by 2050
- Market for disease-modifying therapies: >$10B annually
¶ Key Players and Pipeline
Eisai/Biogen (Lecanemab/Leqembi):
- First disease-modifying AD therapy (2023 approval)
- Confirmatory Phase 4 trial ongoing
- Subcutaneous formulation in development
Eli Lilly (Donanemab/Kisunla):
- Approved November 2024
- Requires tau confirmation for use
- Phase 4 real-world evidence program
Eli Lilly (Remternetug):
- Next-generation oligomer-targeting antibody
- Phase 3 TRAILBLAZER-ALZ 6
- Subcutaneous administration
Acumen Pharmaceuticals (Sabirnetug):
- Differentiated oligomer-selective mechanism
- Phase 2 ALTITUDE-AD in progress
- Potential for earlier-stage intervention
Acumen's approach with Sabirnetug reflects several strategic decisions:
- Oligomer selectivity - May provide improved safety/efficacy compared to plaque-targeting antibodies
- Early intervention focus - Targeting earlier disease stages where maximum benefit expected
- Composite endpoints - iADRS captures functional as well as cognitive benefits
- Optimal dose finding - Phase 2 includes multiple dose levels to inform Phase 3 design
Monoclonal antibodies like Sabirnetug exhibit distinct PK properties:
- Distribution: Limited to vascular compartment; slow distribution into CNS
- Half-life: Extended half-life (~21-28 days) supports less frequent dosing
- Clearance: Fc-mediated clearance; may be affected by target burden
- CSF penetration: Low (~0.1-1% of plasma exposure)
Expected PD effects include:
- Reduced plasma Aβ oligomer levels
- Decreased CSF Aβ42 (reflecting brain clearance)
- Potential for downstream tau effects
- Biomarker changes prior to clinical effects
Comprehensive biomarker program to understand:
- Amyloid PET - Plaque burden change
- CSF Aβ42/40 - Shift toward normalization
- CSF tau/p-tau - Disease progression markers
- Neurofilament light (NfL) - Neurodegeneration marker
- Neuroinflammation markers - Microglial activation status
Given the complex pathophysiology of AD, combination approaches may provide enhanced benefit:
Rationale for combinations:
- Multiple pathways involved in disease
- Synergistic effects possible
- May allow lower doses with maintained efficacy
Potential combinations:
- Aβ antibody + anti-tau therapy
- Aβ antibody + neuroinflammation modulator
- Aβ antibody + symptomatic agents
Future development may incorporate:
- ApoE genotype - Tailored dosing/safety monitoring
- Biomarker profiles - Patient selection based on pathology
- Genetic risk scores - Early intervention in high-risk individuals
- Digital biomarkers - Remote monitoring of treatment response
If Phase 2/3 trials successful, potential expansion to:
- Preclinical AD (cognitively normal, biomarker positive)
- Combination prevention studies
- Early genetic forms of AD (autosomal dominant)
While ALTITUDE-AD is a traditional RCT design, the broader AD field is moving toward innovative trial designs:
Platform Trials:
- Multiple treatments tested simultaneously
- Shared control group improves efficiency
- Adaptive randomization based on interim results
- Example: Alzheimer's Disease Tau Platform (NCT06957418)
Basket Trials:
- Group patients by biomarker rather than diagnosis
- Pathology-driven patient selection
- Efficient for rare subtypes
Umbrella Trials:
- Multiple subtypes within single disease
- Biomarker-stratified assignment to arms
- Personalized medicine approach
Modern AD trials increasingly incorporate remote/digital elements:
- Telehealth visits for safety monitoring
- Digital cognitive assessments (e.g., Cambridge Neuropsychological Test Automated Battery)
- Wearable devices for activity/motor monitoring
- At-home MRI for ARIA monitoring (emerging)
- Electronic patient-reported outcomes (ePRO)
These innovations may improve recruitment, retention, and real-world data collection, potentially accelerating trial timelines.
Successful trials in AD have employed enrichment:
- Biomarker enrichment - Amyloid-positive confirmed via PET or CSF
- Stage enrichment - Early AD (MCI-mild dementia)
- Genetic enrichment - ApoE ε4 carriers for higher risk
- Compliance enrichment - Prior trial experience
ALTITUDE-AD employs multiple enrichment strategies to maximize the probability of detecting treatment effects in this challenging population.
¶ Regulatory Context and Development Pathway
Anti-Aβ antibodies have received accelerated approval based on amyloid reduction:
- Lecanemab - Accelerated approval 2023, full approval 2024
- Donanemab - Accelerated approval 2024
Requirements for full approval:
- Clinical benefit confirmation in post-marketing studies
- Continued safety monitoring
- Real-world effectiveness data
The FDA has issued guidance for AD drug development:
- Early AD population recommended for disease-modifying trials
- Composite endpoints (iADRS, CDR-SB) preferred
- Biomarker validation encouraged but not required
- Confirmatory trial required for accelerated approval
European Medicines Agency perspective:
- Emphasizes clinical relevance over biomarker endpoints
- More conservative on ARIA risk acceptance
- Requires robust clinical outcomes for approval
ICH guidelines support international trial conduct:
- Harmonized inclusion/exclusion across regions
- Consistent endpoint assessment methodology
- Regulatory convergence for approval decisions
¶ Summary and Key Takeaways
ALTITUDE-AD (NCT06335173) represents a significant advancement in Alzheimer's disease drug development:
- Novel target - Aβ oligomers are increasingly recognized as primary toxic species
- Selective approach - Differentiated from plaque-targeting antibodies
- Early intervention - Focus on MCI/mild AD where benefits may be greatest
- Comprehensive biomarkers - Multi-modal assessment of disease modification
- Regulatory pathway - Built on lessons from approved Aβ antibodies
Key facts:
- Enrollment: 542 participants
- Status: Active, not recruiting
- Timeline: 2024-2026
- Primary endpoint: iADRS change at Week 78
- Sponsor: Acumen Pharmaceuticals
The outcomes of ALTITUDE-AD will inform not only Sabirnetug's development but also the broader strategy of oligomer-targeted therapy in AD. Success would validate this approach and potentially expand treatment options for the millions affected by this devastating disease.
Trial Identifier: NCT06335173
Official Title: A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
Alternate Title: ALTITUDE-AD